Article Figures & Data
Figures
- FIGURE 1.
(A) Comparison of body mass of nude mice treated with 17AAG vs. control animals. Animals were treated with 3 × 50 mg/kg 17AAG over 24 h on day 0. (B) Comparison of BT474 tumor growth in nude mice treated with 17AAG vs. control animals.
- FIGURE 2.
Comparison of 68Ga-DOTA-F(ab′)2-herceptin uptake in nude mice with BT474 tumors before and after 17AAG treatment. Animals were treated with 3 × 50 mg/kg of 17AAG over 24 h on day 0 and data are normalized to day –2 uptake.
- FIGURE 3.
microPET images (coronal slice and transverse slice through tumor) of 68Ga-DOTA-F(ab′)2-herceptin uptake in the same mouse with a BT474 tumor at –2 d (A), 1 d (B), 5 d (C), 8 d (D), and 12 d (E) after treatment with 3 × 50 mg/kg of 17AAG over 24 h on day 0. Arrows indicate tumor.
- FIGURE 4.
Comparison of 18F-FDG uptake in nude mice with BT474 tumors before and after 17AAG treatment. Animals were treated with 3 × 50 mg/kg of 17AAG over 24 h on day 0 and data are normalized to day –6 uptake.
Jump to section
Related Articles
Cited By...
- ImmunoPET as Stoichiometric Sensor for Glypican-3 in Models of Hepatocellular Carcinoma
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers
- Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
- Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy
- 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
- In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
- Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
- FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy
- Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model
- Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment
- Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
- Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging
- 89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922
- A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression
- Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy
- Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules
- Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
- Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
- The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
- Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers
- Antibodies and Antimatter: The Resurgence of Immuno-PET
- Tumor Receptor Imaging
- Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
- Chaperoning Drug Development with PET